Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter Syndrome.

Date publication

janvier 2020

Journal

Frontiers in immunology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr FEUGIER Pierre , Pr BROSEUS Julien , Pr FORNECKER Luc-Matthieu

Tous les auteurs :
Augé H, Notarantonio AB, Morizot R, Quinquenel A, Fornecker LM, Hergalant S, Feugier P, Broséus J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33381116

Résumé

Richter Syndrome (RS) is defined as the development of an aggressive lymphoma in the context of Chronic Lymphocytic Leukemia (CLL), with a Diffuse Large B-Cell Lymphoma (DLBCL) histology in 95% cases. RS genomic landscape shares only a few features with DLBCLs and is marked by a wide spectrum of cytogenetic abnormalities. Little is known about RS microenvironment. Therapeutic options and efficacy are limited, leading to a 12 months median overall survival. The new targeted treatments usually effective in CLL fail to obtain long-term remissions in RS.

Mots clés

Richter syndrome, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, genomics, immune checkpoint, immune checkpoint inhibitor, microenvironment

Référence

Front Immunol. 2020 ;11:594841